300404.SHE Guangzhou Boji Medical and Biotechnological Co Ltd
- Market cap
- CNY 4.43B
- P/E
- 76.6x
- P/B
- 4.10x
- ROE
- 6.1%
- Dividend yield
- 0.13%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300404.SHE undervalued?
Graham numberThe Graham number of Guangzhou Boji Medical and Biotechnological Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangzhou Boji Medical and Biotechnological Co Ltd fundamental analysis
No fundamental analysis for Guangzhou Boji Medical and Biotechnological Co Ltd yet.
Guangzhou Boji Medical and Biotechnological Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangzhou Boji Medical and Biotechnological Co Ltd
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. The company offers pre-clinical research, clinical research, and other consulting services. It also provides clinical drug production, pilot test scale-up, process verification batch production, and drug registration and approval services. In addition, it engages…
Full company profileGuangzhou Boji Medical and Biotechnological Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangzhou Boji Medical and Biotechnological Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 72.2M | 131M | 172M | 224M | 260M | 324M | 424M | 556M | 742M | 869M | 976M |
| Gross Profit | 35.1M | 35.8M | 78.5M | 95.3M | 114M | 140M | 161M | 185M | 225M | 236M | 241M |
| Operating Income | 43.1K | -12.4M | 21.7M | 21.2M | 37.8M | 54.5M | 34.8M | 33.0M | 40.7M | 60.1M | 69.7M |
| EBITDA | - | -25.6M | 25.4M | 27.3M | 44.2M | 66.4M | 46.8M | 42.4M | 48.8M | 59.9M | 67.0M |
| Net Income | 2.09M | -24.5M | 7.40M | 6.59M | 17.0M | 38.9M | 27.7M | 24.3M | 28.8M | 30.5M | 65.7M |
| EPS | - | -0.11 | 0.03 | 0.03 | 0.07 | 0.15 | 0.08 | 0.06 | 0.08 | 0.08 | 0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 519M | 575M | 606M | 633M | 750M | 1.14B | 1.27B | 1.43B | 1.45B | 1.63B | 1.72B |
| Total Liabilities | 89.0M | 160M | 182M | 177M | 265M | 292M | 377M | 449M | 449M | 570M | 613M |
| Shareholders' Equity | 428M | 404M | 413M | 423M | 444M | 814M | 855M | 956M | 973M | 1.03B | 1.09B |
| Cash & Short-term Investments | 105M | 133M | 55.2M | 57.4M | 146M | 385M | 307M | 397M | 270M | 326M | 181M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.2M | 26.2M | 27.1M | 85.9K | 97.1M | 30.1M | 28.1M | 36.0M | 26.8M | 87.0M | - |
| Capital Expenditure | 78.2M | 62.5M | 38.0M | 29.0M | 31.4M | 54.0M | 118M | 62.2M | 29.4M | 18.7M | 23.1M |
| Free Cash Flow | - | -36.3M | -11.0M | -28.9M | 65.6M | -23.9M | -89.6M | -26.2M | -2.57M | 68.3M | -35.8M |
| Ratios | |||||||||||
| ROE | 0.5% | -6.1% | 1.8% | 1.6% | 3.8% | 4.8% | 3.2% | 2.5% | 3.0% | 3.0% | 6.1% |
| ROA | 0.4% | -4.3% | 1.2% | 1.0% | 2.3% | 3.4% | 2.2% | 1.7% | 2.0% | 1.9% | 3.8% |
| Net Profit Margin | 2.9% | -18.7% | 4.3% | 2.9% | 6.5% | 12.0% | 6.5% | 4.4% | 3.9% | 3.5% | 6.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Guangzhou Boji Medical and Biotechnological Co Ltd dividends
- Dividend yield
- 0.13%
- Forward dividend
- 0.01 CNY
- Payout ratio
- 19.4%
- Ex-dividend date
- Jun 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 5.92M | 0.02 | 19.4% |
| 2024 | CNY 7.58M | 0.02 | 26.4% |
| 2023 | CNY 8.04M | 0.02 | 33.0% |
| 2022 | CNY 6.84M | 0.02 | 24.7% |
| 2021 | CNY 1.20M | 0.00 | 3.1% |
| 2020 | CNY 3.23M | 0.01 | 19.0% |
| 2019 | CNY 2.39M | 0.01 | 36.3% |
| 2018 | CNY 2.39M | 0.01 | 32.3% |
| 2017 | CNY 2.39M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 2, 2022.
Who owns Guangzhou Boji Medical and Biotechnological Co Ltd
- Insiders 39.77%
- Institutions 1.01%
- Public & others 59.22%
- Shares outstanding 386M
- Free float 250M
Guangzhou Boji Medical and Biotechnological Co Ltd company profile
- Company name
- Guangzhou Boji Medical and Biotechnological Co Ltd
- Ticker
- 300404.SHE
- ISIN
- CNE100001Y00
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 1,198
- Fiscal year end
- December
- Address
- Building A, Vanke Cloud Plaza, Guangzhou, China, 510000
- Phone
- 86 40 0002 0628
- Website
- bojicro.com
About Guangzhou Boji Medical and Biotechnological Co Ltd
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. The company offers pre-clinical research, clinical research, and other consulting services. It also provides clinical drug production, pilot test scale-up, process verification batch production, and drug registration and approval services. In addition, it engages in the screening, evaluation, verification, and trading of technological achievements formed in the process of new drug research and development. The company was formerly known as Guangzhou Boji Medical & Biotechnological Co., Ltd. and changed its name to Boji Medical Technology Co.,Ltd. in September 2021. Boji Medical Technology Co.,Ltd. was founded in 1998 is headquartered in Guangzhou, China.
Guangzhou Boji Medical and Biotechnological Co Ltd management
7- Mr. Tingchun Wang M.D., Ph.D.Founder, Chairman & GM · born 1965
- Ms. Xiu Qing OuDeputy GM, CFO & Director · born 1982
- Ms. Fangqun WeiDeputy GM & Secretary of the Board · born 1986
- Mr. Shaobo WenDeputy General Manager · born 1983
- Ms. Lian ZuoDeputy General Manager · born 1968
- Mr. Zhanpeng ChenAccounting Supervisor
- Qi Kui XiaDeputy GM, Chief Operating Officer (Clinical) & GM of Shanghai Bojikang